Liver cancer drug review: are new treatments better?
NCT ID NCT07233759
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks back at the medical records of 2,500 liver cancer patients treated at a major hospital in Taiwan between 2019 and 2024. It focuses on people who received newer drugs like immunotherapy and targeted therapy instead of the older standard treatment. The goal is to see how long patients lived, how well the cancer responded, and what side effects occurred.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATEZOLIZUMAB are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Taiwan University Hospital
Taipei, 100, Taiwan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a simple scan and blood test outsmart liver cancer?
- Could a vaccine help fight Hard-to-Treat cancers?
- Could a tailored diet before surgery boost liver cancer recovery?
- Can a new PET tracer light up hidden cancers?
- A new test could reveal how radiation affects the liver
- Can an immunotherapy drug keep liver cancer at bay after surgery?